COVID-19 early treatment: real-time analysis of 6,129 studies
COVID-19 involves the interplay of over 200 viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes over 6,100 studies for 180 treatments—over 17 million hours of research.
US authorities believe only three high-profit early treatments
reduce risk (remdesivir, paxlovid, molnupiravir). In reality, many treatments reduce risk,
and 25 low-cost treatments have been approved across 163 countries.
0.5% of 10,000+ proposed treatments show reduced risk.
Treatment to the primary source of initial infection reduces progression and transmission.
Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Methods for increasing internal body temperature, comparable to natural fever, enhancing immune system function.
Many systemic agents reduce risk, and may be required when infection progresses beyond the upper respiratory tract.
High-profit systemic agents are also effective, but have greater access and cost barriers.
Highly effective but rarely used—variant dependence, high cost, IV/SC administration.
Increased risk of severe outcomes and mortality.
Studies show increased mortality with longer followup.
c19early.org
We do not provide medical advice. No treatment is 100% effective, and all may have side effects. Protocols combine multiple treatments. Consult a qualified physician for personalized risk/benefit analysis.
Timeline for when studies showed efficacy - details and limitations.
0.5% of treatments show efficacy.
Top journals that accept positive studies for low cost treatments:
Nutrients,
Scientific Reports,
PLOS ONE,
International Journal of Infectious Diseases,
Frontiers in Medicine,
Cureus,
more...
Treatment cost times median NNT - details and limitations.
0.5% of treatments show efficacy.
All clinical results for selected treatments. 0.5% of treatments show efficacy.
| Random effects meta-analysis of all studies (pooled effects, all stages). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of early treatment studies (pooled effects). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all outcomes are affected by the distribution of outcomes tested, please see detail pages for specific outcome analysis. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of all mortality results (all stages). Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Pooled results across all stages depend on the distribution of stages tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of early treatment mortality results. Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of prophylaxis studies (pooled effects). Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all outcomes are affected by the distribution of outcomes tested, please see detail pages for specific outcome analysis. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of prophylaxis mortality results. Treatments with ≤3 studies with distinct authors or with <25 control events are shown in grey. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of long covid results. Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. | |||||
| Random effects meta-analysis of transmission results. Treatments with ≤3 studies with distinct authors or with <50 control events are shown in grey. Pooled results across all stages and outcomes depend on the distribution of stages and outcomes tested - for example late stage treatment may be less effective and if the majority of studies are late stage this may obscure the efficacy of early treatment. Please see the specific stage and outcome analyses. Protocols typically combine multiple treatments which may be complementary and synergistic, and the SOC in studies often includes other treatments. 0.5% of proposed treatments show efficacy in clinical studies. |
| LATE TREATMENT | ||||
| Physician / Team | Location | Patients | HospitalizationHosp. | MortalityDeath |
| Dr. David Uip (*) | Brazil | 2,200 | 38.6% (850) | 2.5% (54) |
| Dr. Jake Scott (**) | USA | 1,000 | 10.0% (100) | |
| Average | 38.6% | 6.2% | ||
| EARLY TREATMENT PROTOCOLS - 40 physicians/teams | ||||
| Physician / Team | Location | Patients | HospitalizationHosp. | MortalityDeath |
| Dr. Roberto Alfonso Accinelli 0/360 deaths for treatment within 3 days |
Peru | 1,265 | 0.6% (7) | |
| Dr. Mohammed Tarek Alam patients up to 84 years old |
Bangladesh | 100 | 0.0% (0) | |
| Dr. Oluwagbenga Alonge | Nigeria | 310 | 0.0% (0) | |
| Dr. Raja Bhattacharya up to 88yo, 81% comorbidities |
India | 148 | 1.4% (2) | |
| Dr. Flavio Cadegiani | Brazil | 3,450 | 0.1% (4) | 0.0% (0) |
| Dr. Alessandro Capucci | Italy | 350 | 4.6% (16) | |
| Dr. Shankara Chetty | South Africa | 8,000 | 0.0% (0) | |
| Dr. Deborah Chisholm | USA | 100 | 0.0% (0) | |
| Dr. Ryan Cole | USA | 400 | 0.0% (0) | 0.0% (0) |
| Dr. Marco Cosentino earlier treatment results were better |
Italy | 392 | 6.4% (25) | 0.3% (1) |
| Dr. Jeff Davis | USA | 6,000 | 0.0% (0) | |
| Dr. Dhanajay | India | 500 | 0.0% (0) | |
| Dr. Bryan Tyson & Dr. George Fareed | USA | 20,000 | 0.0% (6) | 0.0% (4) |
| Dr. Raphael Furtado | Brazil | 170 | 0.6% (1) | 0.0% (0) |
| Rabbi Yehoshua Gerzi | Israel | 860 | 0.1% (1) | 0.0% (0) |
| Dr. Heather Gessling | USA | 1,500 | 0.1% (1) | |
| Dr. Ellen Guimarães | Brazil | 500 | 1.6% (8) | 0.4% (2) |
| Dr. Syed Haider | USA | 4,000 | 0.1% (5) | 0.0% (0) |
| Dr. Mark Hancock | USA | 24 | 0.0% (0) | |
| Dr. Sabine Hazan | USA | 1,000 | 0.0% (0) | |
| Dr. Mollie James | USA | 3,500 | 1.1% (40) | 0.0% (1) |
| Dr. Roberta Lacerda | Brazil | 550 | 1.5% (8) | 0.4% (2) |
| Dr. Katarina Lindley | USA | 100 | 5.0% (5) | 0.0% (0) |
| Dr. Ben Marble | USA | 150,000 | 0.0% (4) | |
| Dr. Edimilson Migowski | Brazil | 2,000 | 0.3% (7) | 0.1% (2) |
| Dr. Abdulrahman Mohana | Saudi Arabia | 2,733 | 0.0% (0) | |
| Dr. Carlos Nigro | Brazil | 5,000 | 0.9% (45) | 0.5% (23) |
| Dr. Benoit Ochs | Luxembourg | 800 | 0.0% (0) | |
| Dr. Ortore | Italy | 240 | 1.2% (3) | 0.0% (0) |
| Dr. Valerio Pascua one patient already on oxygen died |
Honduras | 415 | 6.3% (26) | 0.2% (1) |
| Dr. Sebastian Pop | Romania | 300 | 0.0% (0) | |
| Dr. Brian Proctor | USA | 869 | 2.3% (20) | 0.2% (2) |
| Dr. Anastacio Queiroz | Brazil | 700 | 0.0% (0) | |
| Dr. Didier Raoult | France | 8,315 | 2.6% (214) | 0.1% (5) |
| Dr. Karin Ried up to 99yo, 73% comorbidities |
Turkey | 237 | 0.4% (1) | |
| Dr. Roman Rozencwaig patients up to 86 years old |
Canada | 80 | 0.0% (0) | |
| Dr. Vipul Shah | India | 8,000 | 0.1% (5) | |
| Dr. Silvestre Sobrinho | Brazil | 116 | 8.6% (10) | 0.0% (0) |
| Dr. Unknown | Brazil | 957 | 1.7% (16) | 0.2% (2) |
| Dr. Vladimir Zelenko | USA | 2,200 | 0.5% (12) | 0.1% (2) |
| Average | 2.2% | 0.1% | ||
Physician results with early combined treatment protocols compared to
no early treatment. These results are subject to selection and ascertainment
bias and more accurate analysis requires details of the patient populations
and followup, however results are consistently better across many teams, and consistent
with the extensive controlled trial evidence that shows a significant
reduction in risk with many early treatments, and improved results with the
use of multiple treatments in combination.
(*) Dr. Uip reportedly prescribed early treatment for himself, but not for
patients1.
(**) Dr. Scott reports treating hundreds of patients and losing over a hundred,
but has not provided specific numbers2.
Dr. Scott reports following (and helping create) US guidelines.
| Lehr | 450 patient prophylaxis RCT: 72% fewer symptomatic cases (p=0.02), 69% fewer cases (p=0.03), and 34% faster viral clearance (p<0.0001) |
| Abiri | Cross-sectional study of 29 hospitalized COVID-19 patients four weeks post-infection showing increased DNA damage correlating with disease severity. |
| Bruno | Prospective study of 2,390 adults across 18 countries showing higher large-artery stiffness 6 months after COVID-19. |
| Yin | Review of thrombotic complications in COVID-19 patients and anticoagulation strategies. Authors note that COVID-19 induces a prethrombotic state.. |
| Hanson | Review of host immune response (HR) diagnostics for infectious diseases, which measure gene expression profiles or inflammatory protein.. |
| Jaurrieta-Largo | Retrospective 338 hospitalized COVID-19 patients in Spain showing that genetic polymorphisms in inflammation, vitamin D, and ACE2-related genes can.. |
| de la Puente | Bioequivalence study of 66 healthy Mexican volunteers comparing two oral ivermectin formulations, showing significant pharmacokinetic variability... |
Recent studies (see the individual treatment pages for all studies):
Sep 2 |
et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2025.4283 | Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections |
| 72% fewer symptomatic cases (p=0.02), 69% fewer cases (p=0.03), and 34% faster viral clearance (p<0.0001). RCT 450 healthy adults showing lower PCR-confirmed and symptomatic SARS-CoV-2 infections with azelastine 0.1% nasal spray (1 puff/nostril 3x/day for 56 days) versus placebo. The placebo formulation (hypromellose) may also have efficacy vi.. | ||
Sep 2 |
et al., medRxiv, doi:10.1101/2025.08.29.25334732 | Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19 |
| 6-month followup of RECOVERY patients. Results are reported within the respective trials for each treatment. | ||
Aug 21 |
et al., Scientific Reports, doi:10.1038/s41598-025-16092-4 | A Triple-blind randomized controlled trial on the effects of turmeric versus ginger on inflammatory biomarkers in patients with COVID-19 |
| RCT 144 COVID-19 outpatients showing a significant reduction in inflammatory markers (CRP and ESR) with both turmeric and ginger compared with placebo. There was no significant difference between groups for LDH or WBC. Baseline age differ.. | ||
Aug 20 |
et al., Frontiers in Public Health, doi:10.3389/fpubh.2025.1462286 | Saline nasal irrigation and gargling in COVID-19: Part II. Outcomes in Omicron and risk–benefit for self-care |
| Systematic review of saline nasal irrigation (SNI) and gargling for COVID-19. Authors reviewed 14 studies with 2,389 patients with Omicron infection and found that early initiation of SNI and gargling consistently reduced viral loads and .. | ||
Aug 18 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms26167975 | A Machine Learning Approach to Understanding the Genetic Role in COVID-19 Prognosis: The Influence of Gene Polymorphisms Related to Inflammation, Vitamin D, and ACE2 |
| Retrospective 338 hospitalized COVID-19 patients in Spain showing that genetic polymorphisms in inflammation, vitamin D, and ACE2-related genes can predict COVID-19 pneumonia, mortality, and rehospitalization with high accuracy. | ||
Aug 15 |
et al., The Egyptian Journal of Internal Medicine, doi:10.1186/s43162-025-00505-x | Mortality related to COVID-19 in kidney transplant recipients, dialysis patients and patients with chronic kidney disease: a cohort study |
| Retrospective 250 COVID-19 patients with chronic kidney disease. Authors note in the abstract that azithromycin and vitamin C were associated with better outcomes, however no details are provided in the paper. | ||
Aug 14 |
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2025.08.003 | Peginterferon lambda for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomised trial |
| 32% worse 7-point scale results (p=0.49). RCT 97 hospitalized COVID-19 patients showing no significant benefit with peginterferon lambda. | ||
Aug 13 |
et al., Pharmaceuticals, doi:10.3390/ph18081193 | Variations in Plasma Levels of Orally Administered Ivermectin Could Hamper Its Potential Drug Repositioning: Results of a Bioequivalence Study in Mexican Population |
| Bioequivalence study of 66 healthy Mexican volunteers comparing two oral ivermectin formulations, showing significant pharmacokinetic variability. The study found high inter- and intra-subject variability (>50% coefficient of variation) i.. | ||
Aug 12 |
et al., medRxiv, doi:10.1101/2025.08.08.25333305 | Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial |
| RCT 2,983 outpatients showing lower incidence of long COVID symptoms with metformin, without statistical significance. The primary endpoint of post-acute sequelae of COVID-19 or death at day 180 occurred in 2.3% of metformin patients vs 3.. | ||
We aim to cover the most promising early treatments for
COVID-19. We use pre-specified effect extraction criteria that prioritizes
more serious outcomes, for details see methods. For specific
outcomes and different treatment stages see the individual pages. Not all
treatments are covered here, effectiveness has been reported for many other treatments in studies.
Of the 6,129 studies,
2,871 present results comparing with a control group,
2,649 are treatment studies, and
222 analyze outcomes based on serum levels. There are
123 animal studies,
227 in silico studies,
436 in vitro studies,
487 reviews,
and 249 meta analyses.
References
medicospelavidacovid19.com.br, medicospelavidacovid19.com.br/editoriais/folha-de-s-paulo-revela-numeros-de-david-uip-veja-a-comparacao-com-medicos-que-fazem-tratamento-precoce/.
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.